History matters: Preventing severe allergic transfusion reactions.

IF 1.9 4区医学 Q2 PATHOLOGY

American journal of clinical pathology Pub Date : 2025-10-04 DOI:10.1093/ajcp/aqaf093

Edina A Wappler-Guzzetta, Asad Shafiq, Umaima Asad, Tushar Chakravarty, Elena G Nedelcu

{"title":"History matters: Preventing severe allergic transfusion reactions.","authors":"Edina A Wappler-Guzzetta, Asad Shafiq, Umaima Asad, Tushar Chakravarty, Elena G Nedelcu","doi":"10.1093/ajcp/aqaf093","DOIUrl":null,"url":null,"abstract":"Objective: Prior studies have shown that pretransfusion medication is not effective in preventing allergic transfusion reactions (ATRs), but these studies did not consider the patient's history of ATR. This study evaluated whether pretransfusion antiallergy medications decrease the chance of ATRs in patients with a history of severe ATR.Methods: This single-center, retrospective study investigated the effect of pretransfusion medications on preventing ATRs in patients with a history of at least 1 severe ATR between March 2018 and January 2024. Patient demographics as well as clinical and transfusion reaction data were collected from our electronic health record (EHR) system. Data were analyzed using SPSS (IBM Corp) and machine learning in Python, version 3.12.4.Results: In our cohort, 53 patients aged 5 weeks to 94 years with 2767 analyzable transfusion encounters had experienced 88 lifelong mild and severe ATRs. Premedication (P = .021), regular antiallergy medication (P < .001), and washing/volume reduction (P = .032) were associated with a statistically significantly lower chance of developing ATRs in our patient population.Conclusions: Patients with at least 1 severe ATR benefit from pretransfusion administration of antiallergy medications.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"626-633"},"PeriodicalIF":1.9000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495513/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of clinical pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajcp/aqaf093","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Prior studies have shown that pretransfusion medication is not effective in preventing allergic transfusion reactions (ATRs), but these studies did not consider the patient's history of ATR. This study evaluated whether pretransfusion antiallergy medications decrease the chance of ATRs in patients with a history of severe ATR.

Methods: This single-center, retrospective study investigated the effect of pretransfusion medications on preventing ATRs in patients with a history of at least 1 severe ATR between March 2018 and January 2024. Patient demographics as well as clinical and transfusion reaction data were collected from our electronic health record (EHR) system. Data were analyzed using SPSS (IBM Corp) and machine learning in Python, version 3.12.4.

Results: In our cohort, 53 patients aged 5 weeks to 94 years with 2767 analyzable transfusion encounters had experienced 88 lifelong mild and severe ATRs. Premedication (P = .021), regular antiallergy medication (P < .001), and washing/volume reduction (P = .032) were associated with a statistically significantly lower chance of developing ATRs in our patient population.

Conclusions: Patients with at least 1 severe ATR benefit from pretransfusion administration of antiallergy medications.

查看原文本刊更多论文

历史问题：预防严重的过敏性输血反应。

目的：以往的研究表明，输血前药物治疗对预防过敏性输血反应（ATRs）无效，但这些研究没有考虑患者的ATR史。本研究评估输血前抗过敏药物是否能降低有严重ATR病史的患者发生ATR的几率。方法：本单中心回顾性研究调查了2018年3月至2024年1月期间至少有1次严重ATR病史的患者输血前药物预防ATR的效果。患者人口统计数据以及临床和输血反应数据从我们的电子健康记录（EHR）系统收集。数据分析使用SPSS （IBM Corp）和Python 3.12.4版本的机器学习。结果：在我们的队列中，53例患者年龄在5周到94岁之间，有2767例可分析的输血经历，经历了88例终身轻度和重度atr。用药前(P =。结论：至少有1例严重ATR的患者可从输血前给予抗过敏药物中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of clinical pathology 医学-病理学

CiteScore

7.70

自引率

2.90%

发文量

367

审稿时长

3-6 weeks

期刊介绍： The American Journal of Clinical Pathology (AJCP) is the official journal of the American Society for Clinical Pathology and the Academy of Clinical Laboratory Physicians and Scientists. It is a leading international journal for publication of articles concerning novel anatomic pathology and laboratory medicine observations on human disease. AJCP emphasizes articles that focus on the application of evolving technologies for the diagnosis and characterization of diseases and conditions, as well as those that have a direct link toward improving patient care.